<p>Prediction Of Serum Digoxin Concentration Using Estimated Glomerular Filtration Rate In Thai Population</p>

Abstract

Purpose: Serum digoxin concentration (SDC) monitoring may be unavailable in some healthcare settings. Predicted SDC comes into play in the efficacy and toxicity monitoring of digoxin. Renal function is the important parameter for predicting SDC. This study was conducted to compare measured and predicted SDC when using creatinine clearance (CrCl) from Cockcroft-Gault (CG) equation and estimated glomerular filtration rate (eGFR) calculated from CKD-Epidemiology Collaboration (CKD-EPI), re-expressed Modification of Diet in Renal Disease (Re-MDRD4), Thai-MDRD4, and Thai-eGFR equations in Sheiner's and Konishi's pharmacokinetic models. Patients and methods: In this retrospective study, patients with cardiovascular disease with a steady-state of SDC within 0.5-2.0 mcg/L were enrolled. CrCl and studied eGFR adjusted for body surface area (BSA) were used in the models to determine the predicted SDC. The discrepancies of the measured and the predicted SDC were analyzed and compared. Results: One hundred and twenty-four patients ranging in age from 22 to 88 years (median 60 years, IQR 50.2, 69.2) were studied. Their serum creatinine ranged from 0.40 to 1.80 mg/dL (median 0.90 mg/dL, IQR 0.79, 1.10). The mean±SD of measured SDC was 1.12±0.34 mcg/L. In the Sheiner's model, the mean predicted SDC was calculated by using the CG and the BSA adjusted CKD-EPI equations and was not different when compared with the measured levels (1.10±0.36 mcg/L (p=0.669) and 1.08±0.42 mcg/L (p=0.374), respectively). The CG, CKD-EPI, and Re-MDRD4 equations were a better fit for patients with creatinine ≥0.9 mg/dL for prediction with minimal errors. In the Konishi's model, the predicted SDC using the CG and the studied eGFR equation was lower than the measured SDC (p<0.05). Conclusion: In Sheiner's model, the CG and the BSA adjusted CKD-EPI equations should be used for predicting SDC, especially in patients with serum creatinine ≥0.9 mg/dL. The other studied eGFRs underestimated SDC in both Sheiner's and Konishi's model.

Transplacental Therapeutic Drug Monitoring in Pregnant Women with Fetal Tachyarrhythmia Using HPLC-MS/MS

“…The polymorphisms of genes coding the transporters involved in detoxification changes the individual features of the drug pharmacokinetics [17,18,21,50]. The data obtained confirmed the expediency of genotyping a pregnant woman for the 3435C > T polymorphism of the ABCB1 xenobiotic detoxification gene.…”

“…The adverse effects occurred with a frequency of 30-38.8% and included mild headache, moderate nausea, diarrhea, and may be reduced or eliminated by reducing the dose [23,48]. There is a genetic predisposition to the antiarrhythmic drugs variations in pharmacokinetics, pharmacodynamics, and side effects [20,21,40,[49][50][51]. Of particular interest is the influence of the xenobiotic metabolization gene, ABCB1, polymorphisms to the transplacental ART efficacy.…”

Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function

“…We usually tend to avoid the administration of digoxin in patients with renal dysfunction because renal impairment is a well-recognized risk factor for digoxin toxicity. 21) The Digitalis in Acute Atrial Fibrillation (DAAF) trial, which examined the effects of intravenously administered digoxin in patients with AF, described the effective dose of digoxin for controlling the HR in detail. 8) The mean total dose of digoxin during the study period was less in the present study than in the DAAF trial (0.43 ± 0.13 mg versus 0.88 ± 0.35 mg).…”